A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus

2023-509188-26-00 Protocol GA43191 Human pharmacology (Phase I) - Other Ended

Start 27 Oct 2022 · End 18 Dec 2024 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol GA43191

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 18
Countries 1
Sites 2

Systemic Lupus Erythematosus (SLE)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
27 Oct 2022 → 18 Dec 2024
Decision date (initial)
2024-06-24
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509188-26-00
EudraCT number
2021-001565-20

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Systemic Lupus Erythematosus (SLE)

VersionLevelCodeTermSystem organ class
21.1 PT 10042945 Systemic lupus erythematosus 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 7 2
Rest of world
United States, Moldova, Republic of
11

Investigational sites

Poland

2 sites · Ended
Uniwersytecki Szpital Kliniczny W Poznaniu
N/A, Ul. Dluga 1/2, 61-848, Poznan
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy
Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Ul. Kornela Ujejskiego 75, 85-168, Bydgoszcz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2022-10-27 2024-12-17 2023-01-30 2023-11-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-27 Poland Acceptable
2024-06-21
2024-06-24
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-11-20 Poland Acceptable
2024-06-21
2024-11-20
3 SUBSTANTIAL MODIFICATION SM-1 2024-12-02 Poland Acceptable
2025-02-03
2025-02-10